Exhibit 99.1

            CYTOMEDIX SECURES SECOND DEPUY SPINE LICENSING AGREEMENT

License Adds Additional Fields of Use; Modifies Previous Agreement's Exclusivity


         ROCKVILLE, Maryland - March 8, 2005 - Cytomedix, Inc. (CYME:OTC.BB)
today announced that it has entered into a second licensing agreement with DePuy
Spine, Inc., a Johnson and Johnson company. The additional license of
Cytomedix's Knighton patent (US Patent No. 5,165,938) is for all applications of
its autologous platelet releasate therapy, excluding treatment of chronic
wounds, such as pressure ulcers, venous stasis or diabetic foot ulcers.

         The company also said that DePuy Spine's existing exclusive licensing
agreement for spinal, orthopedic and neurosurgical applications would be
converted to a non-exclusive license to practice in those fields. Financial
details of the new agreement were not disclosed.

         "Depuy Spine has been a licensee of Cytomedix's technology since 2001,
and we are pleased to announce the broadening of our license arrangements with
them," said Dr. Kshitij Mohan, chief executive officer of Cytomedix.

         "Today's announcement represents another milestone in Cytomedix's
previously announced strategy of broadly licensing the use of our technology
across a breadth of clinical applications. We continue to believe our technology
is gaining increased awareness and acceptance by medical companies, healthcare
providers and patients alike. The agreements announced today will permit
Cytomedix to pursue new licensing relationships with customers interested in
licensing our technology for orthopedic, spinal and neurosurgical applications,
and we believe it provides Cytomedix with increased opportunities to negotiate
license arrangements with parties that are interested in licenses in multiple
fields of use. Cytomedix will continue to aggressively pursue these additional
licensing opportunities. At the same time, we will vigorously defend our
intellectual property in the courts through legal measures when necessary,"
Mohan said.

ABOUT CYTOMEDIX

         Cytomedix, Inc. is a biotechnology company specializing in processes
and products derived from autologous platelet releasates for uses in the
treatment of wounds and other applications. The current offering is the
AutoloGel(TM) System, a technology that utilizes an autologous platelet gel
composed of multiple growth factors and fibrin matrix. The company is conducting
a well-controlled, blinded, prospective, multi-center clinical trial on the use
of its technology in healing diabetic foot ulcers. Cytomedix is working with
healthcare providers to offer an advanced therapy at the point-of-care in
multiple settings. Additional information is available at: www.cytomedix.com.

FORWARD LOOKING STATEMENTS

         Statements contained in this press release not relating to historical
facts are forward-looking statements that are intended to fall within the safe
harbor rule for such statements under the Private Securities Litigation Reform
Act of 1995. The information contained in the forward-looking statements is
inherently uncertain, and Cytomedix's actual results may differ materially due
to a number of factors, many of which are beyond Cytomedix's ability to predict
or control, including among others, the increase or decrease in royalties as a
result of the new agreement with DePuy, governmental regulation, acceptance by
the medical community and competition. These forward-looking statements are
subject to known and unknown risks and uncertainties that could cause actual
events to differ from the forward-looking statements. More information about
some of these risks and uncertainties may be found in the reports filed with the
Securities and Exchange Commission by Cytomedix, Inc.